UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ to_______________ Commission file number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada 30-0983531 State or othe ...

Biotricity, Inc. (NASDAQ:BTCY) Q2 2023 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Valter Pinto - Managing Director, KCSA Strategic Communications Waqaas Al-Siddiq - Chairman, Chief Executive Officer & Founder John Ayanoglou - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Michael Donovan - H.C. Wainwright Operator Good day, and welcome to the Biotricity's Fiscal Second Quarter 2023 Financial Results Conference Call. Today's c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share BTCY The NASDAQ Stock Market LLC Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ ...

Biotricity, Inc. (OTC:BTCY) Q1 2023 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Valter Pinto - Managing Director, KCSA Strategic Communications Waqaas Siddiq - Chairman, Chief Executive Officer and Founder John Ayanoglou - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital markets Kevin Dede - HC Wainwright Operator Good day and welcome to the Biotricity's Fiscal First Quarter 2023 Financial Results Conference Call. Today's conference is b ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share BTCY The NASDAQ Stock Market LLC Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ to__ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its charter) NEVADA 30-0983531 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identif ...

Biotricity, Inc. (OTC:BTCY) Q3 2022 Earnings Conference Call February 15, 2022 4:15 PM ET Company Participants Waqaas Al-Siddiq – Chairman, Chief Executive Officer and Founder John Ayanoglou – Chief Financial Officer Conference Call Participants Allen Klee – Maxim Group Tim Moore – Zacks Small Cap Research Chet White – Helios Alpha Operator Good day, and welcome to Biotricity's Fiscal 2022 Third Quarter Financial Results Conference Call. Today's conference is being recorded. At this time, I would like to tu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share BTCY The NASDAQ Stock Market LLC Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ ...

Biotricity Inc. (OTC:BTCY) Q2 2022 Earnings Conference Call November 4, 2021 5:00 PM ET Company Participants Mark Forney – MKR Investor Relations Waqaas Al-Siddiq – Founder and Chief Executive Officer John Ayanoglou – Chief Financial Officer Conference Call Participants Allen Klee – Maxim Chet White – Helios Alpha Spencer Kirschman – H.C. Wainwright Operator Good day, and welcome to Biotricity's Fiscal Second Quarter 2022 Financial Results Conference Call. Today’s conference is being recorded. At this time, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share BTCY The NASDAQ Stock Market LLC Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ ...